Cyrus M. Sayehli

Wuerzburg, BY, DE 
Wuerzburg, BY, DE 

Overview

Cyrus Sayehli practices practicing medicine in Wuerzburg, Germany.

His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Neuroendocrine Tumor, and Sezary Syndrome.

He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Wuerzburg, BY, Germany
Other Locations
Dresden, SN, Germany
Munich, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: AMG 596, AMG 404
Study Phase: Phase 1
View 1 Less Clinical Trial

17 Total Publications

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
Journal: Journal of hematology & oncology
Published: March 25, 2026

Frequently Asked Questions about Cyrus M. Sayehli

Is Cyrus M. Sayehli a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Cyrus M. Sayehli is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cyrus M. Sayehli participate in research or clinical trials?

Yes. Cyrus M. Sayehli has published 17 articles and abstracts on conditions like Lung Cancer. You can view a list of Cyrus M. Sayehli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sayehli's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile